We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Department of Anesthesiology

You are here

DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.

TitleDARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.
Publication TypeJournal Article
Year of Publication1984
AuthorsHemmings HC, Nairn AC, Greengard P
JournalJ Biol Chem
Volume259
Issue23
Pagination14491-7
Date Published1984 Dec 10
ISSN0021-9258
KeywordsAmino Acids, Animals, Carrier Proteins, Cattle, Caudate Nucleus, Dopamine and cAMP-Regulated Phosphoprotein 32, Electrophoresis, Polyacrylamide Gel, Histones, Intracellular Signaling Peptides and Proteins, Kinetics, Molecular Weight, Nerve Tissue Proteins, Neurons, Phosphoproteins, Phosphorus Radioisotopes, Phosphorylation, Proteins
Abstract

DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein, Mr = 32,000) is a cytosolic neuronal phosphoprotein enriched in dopamine-innervated brain regions which, in its phosphorylated form, acts as an inhibitor of protein phosphatase 1. We have compared the phosphorylation of purified DARPP-32 with that of purified phosphatase inhibitor 1, a widespread inhibitor of protein phosphatase 1. Purified cyclic AMP-dependent protein kinase and cyclic GMP-dependent protein kinase each catalyzed the maximal incorporation of 0.9-1.1 mol of [32P]phosphate/mol of DARPP-32 or phosphatase inhibitor 1, with phosphorylation occurring on threonine residues. Evidence for the existence of a single phosphorylation site in each substrate protein was obtained by two-dimensional thin-layer phosphopeptide mapping of thermolytic digests. Initial rate studies of the phosphorylation of DARPP-32 yielded an apparent Km of 2.4 microM and a kcat of 2.7 S-1 for the catalytic subunit of cyclic AMP-dependent protein kinase, and an apparent Km of 5.4 microM and a kcat of 2.3 S-1 for cyclic GMP-dependent protein kinase. These in vitro results are compatible with a physiological role for the phosphorylation of DARPP-32 by either protein kinase in vivo. Similar studies with phosphatase inhibitor 1 yielded an apparent Km of 5.0 microM and a kcat of 1.4 S-1 for the catalytic subunit of cyclic AMP-dependent protein kinase, and an apparent Km of 25.0 microM and a kcat of 1.2 S-1 for cyclic GMP-dependent protein kinase. A synthetic nonapeptide, corresponding to the phosphorylation site of DARPP-32, was phosphorylated with apparent Km values of 1.12 mM and 1.86 mM and kcat values of 0.22 S-1 and 3.4 S-1 for cyclic AMP-dependent and cyclic GMP-dependent protein kinase, respectively.

Alternate JournalJ. Biol. Chem.
PubMed ID6501303
Grant ListGM-07205-09 / GM / NIGMS NIH HHS / United States
MH-17387 / MH / NIMH NIH HHS / United States
NS-08440 / NS / NINDS NIH HHS / United States